Atricure announces approval for the cryoice™ platform in japan
Mason, ohio--(business wire)--atricure, inc. (nasdaq: atrc), a leading innovator in treatments for atrial fibrillation (afib) and left atrial appendage (laa) management, today announced that it has received approval from the japanese ministry of health, labor and welfare (mhlw) for its cryoice™ platform and cryo2 cryoablation probe. the approval marks the first time that these products will be available in the japanese market. “we are pleased to have this approval in hand, and to be able to bring our cryoablation products to the japanese market,” said mike carrel, president and ceo of atricure. “this new approval will augment our offerings in the japanese market and offer a leading solution to cardiac surgeons and the japanese patients for the treatment of afib.” the company’s distributor in japan, century medical inc. (cmi), worked closely with atricure to secure approval. product will be immediately available for sale as soon as the reimbursement application is completed, which is expected in the fourth quarter. “japanese surgeons have been waiting a long time for this moment. we believe many patients will benefit from this technology and look forward to bringing it to market,” said takahiko motani, president and ceo of cmi. about atricure atricure, inc. is a medical device company that provides innovative solutions designed to decrease the global afib epidemic. atricure’s isolator® synergy™ ablation system is the first and only surgical device approved for the treatment of persistent and longstanding persistent forms of afib in patients undergoing certain open concomitant procedures. atricure’s atriclip® left atrial appendage management (laam) exclusion device is the most widely sold device worldwide that is indicated for the occlusion of the left atrial appendage. atricure believes electrophysiologists and cardiothoracic surgeons are adopting its technologies for the treatment of afib and reduction of afib related complications. afib affects more than 33 million people worldwide. for more information, visit atricure.com or follow us on twitter @atricure.
ATRC Ratings Summary
ATRC Quant Ranking
You've reached your free article limit.
Want To Read More Articles?
See what it all means for your stocks with premium tools
Stockprices is a weekly video covering what moved markets
this week, featuring a panel of Stockprices editors. It is published by the
close of trading on Fridays. Hosted by Nathaniel E. Baker, contributing editor,
and featuring: Aaron Task, VP Contributor Content and co-host Stockprices's Alpha
Trader podcast; Brad Olesen, VP News; Steve Alpher, Managing Editor News, co-host
Alpha Trader.
Unsubscribe From All
You successfully activated
“Only Essentials”
Confirm Upgrade
Your subscription will be moved to the annual plan. Service will automatically renew unless cancelled. No Refunds. Click upgrade to confirm.
Stockprices uses Plaid to connect you account
Connect effortlessly
Plaid lets you securely connect your financial accounts in seconds
Your data belongs to you
Plaid doesn't sell personal info, and will only use it with your permission